AOD-9604 for Stubborn Fat: 12-Week Test
AOD-9604 for Stubborn Fat: 12-Week Test is best understood as a clinical decision topic, not a shortcut. The evidence, pharmacy source, dose plan, contraindications, and follow-up matter more than any single success story online.
Twelve weeks ago, my friend Marcus in Austin pinched the same roll of lower-abdominal fat he’s been staring at for three years and said something that stuck with me: “I can deadlift 405, I eat like a monk, and this thing won’t budge. It’s like it has its own zip code.” Marcus is 41, runs a small engineering firm, and his DEXA puts him at 17.4 percent body fat. He’s not overweight. He just has a pocket of fat that doesn’t care about discipline.
I know the feeling. I started this 12-week test of compounded AOD-9604 because I share Marcus’s problem and because AOD-9604 is one of the most aggressively mispresented peptides on the internet. The marketing claims routinely outrun the published evidence by a wide margin, and I wanted to see what actually happens when you run it by the book, with real measurements, against a locked training and nutrition protocol.
Compliance frame. AOD-9604 is a synthetic fragment of human growth hormone (residues 176 to 191), originally developed as an anti-obesity agent. It is not FDA-approved for any human indication in the United States. It is accessed through 503A compounding pharmacies for individual patient prescriptions prepared based on prescriber clinical judgment. The FDA placed AOD-9604 on the 503A bulks list under review in 2023. This is not medical advice.
The Starting Line
44-year-old man. 178 pounds at 5-foot-11. Body fat by DEXA at 18.2 percent. Four days a week of lifting, two sessions of zone 2 cardio, roughly 2,400 calories with 175 grams of protein. Sleep is consistent. By any reasonable standard, I’m in solid shape for my age.
The problem is a localized fat deposit on the lower abdomen and flanks that has been immovable through a full year of consistent training, including a dedicated 12-week caloric deficit. During that deficit, total weight came down 8 pounds. The localized deposit was visually unchanged. It was like draining a swimming pool but leaving a puddle in the corner.
My doctor and I went through the realistic options:
- Accept it. It’s aesthetic, not medical.
- Another aggressive deficit. Already tried. The stubborn fat laughed at it.
- GLP-1 medication (semaglutide or tirzepatide). Possible, but probably more firepower than this situation warranted.
- A peptide trial with AOD-9604, which is theorized to have effects on adipocyte lipolysis that may be more pronounced in certain fat depots.
We picked option 4 as the next experiment, with explicit before-and-after evaluation built in.
The Protocol
- AOD-9604: 500 mcg subcutaneous, once daily in the morning before training (or before fasted cardio on non-training days)
- Injection site: alternating abdominal quadrants
- Duration: 12 weeks
- Everything else held constant: same training, same calories (intentionally not cutting), same protein intake
- Baseline assessment: DEXA, weight, waist measurement at navel and at hip, photographs under consistent lighting
- Repeat assessment: same battery at 6 and 12 weeks
The point of holding everything else constant was simple. If something changes, I want to know it was the peptide, not a sneaky 200-calorie-a-day deficit I didn’t notice.
What the Evidence Actually Shows (and What It Doesn’t)
Here’s the thing about AOD-9604: the published human data is thinner than the marketing ecosystem suggests. The peptide was developed by Metabolic Pharmaceuticals as an obesity treatment candidate. Phase IIb trials in obese adults showed modest weight loss, on the order of 2 to 3 pounds over 12 weeks at the studied doses, with a generally clean side effect profile. The development program did not advance to phase III. The reason? The effect size was insufficient to meet commercial endpoints. In pharma terms, it worked a little, but not enough to build a billion-dollar drug around.
Some of the claims you’ll see online, “fat loss without growth hormone effects,” “targeted spot reduction,” go well beyond the trial data. The trials showed modest overall weight reduction, not localized spot reduction. The mechanism of selective lipolysis in certain fat depots has some support from preclinical work, but it’s not strongly demonstrated in humans.
I went in with recalibrated expectations. Realistic upside: modest fat loss with possibly some depot-selective effect. Realistic downside: no meaningful effect at all. Both outcomes were worth documenting.
Weeks 1 Through 8: The Long Plateau
The first month produced nothing visible. Weight bounced around in a 2-pound noise band. Waist measurements were unchanged. No injection-site reactions. No subjective effects of any kind. No “I feel leaner” moments. Just the same body in the mirror.
At the 6-week DEXA, total body fat was 17.9 percent (down 0.3 percent from baseline). Total body fat in pounds was down about 0.4 pounds. Visceral fat was down a small but measurable amount. Subcutaneous abdominal fat was essentially unchanged.
Weeks 5 through 8 showed slightly more measurable movement. Waist at navel went from 33.5 inches to 33.25 inches by week 8. Photographs at week 8 versus week 0 showed a very subtle change in lower abdominal contour. Not dramatic. The kind of thing where you flip back and forth between photos and think “maybe?” rather than “definitely.”
No side effects. The injection routine was uneventful to the point of boredom.
I was starting to suspect that the effect, if any, operated at the level of small changes over months rather than dramatic changes over weeks. Which, for what it’s worth, is exactly what the published trial data predicts.
Weeks 9 Through 12: Final Assessment
End-of-protocol numbers:
- Weight: 176 pounds (down 2 pounds from baseline)
- Body fat by DEXA: 17.6 percent (down 0.6 percent from baseline)
- Total body fat in pounds: down 1.4 pounds
- Visceral fat: down a small but measurable amount
- Waist at navel: 33 inches (down 0.5 inches)
- Waist at hip: 35 inches (down 0.25 inches)
- Photographs: subtle visible change in lower abdominal contour
The trajectory was modest, gradual, and consistent with the published trial data. No depot-selective miracle. Just a small overall fat reduction that happened to show modestly in the area I cared about.
The IGF-1 Question
This is the detail that matters most if you’re evaluating AOD-9604’s safety profile. The peptide is a fragment of growth hormone, but it’s theorized to retain GH’s lipolytic effects without driving the GH-axis effects that lead to IGF-1 elevation. That theory matters because chronically elevated IGF-1 carries real risk.
I measured IGF-1 at baseline, at 6 weeks, and at 12 weeks. It stayed flat throughout. No detectable change. No changes in glucose either, and no changes in any other lab parameter I tracked. The side effect profile across 12 weeks of daily subcutaneous injection was essentially nothing. Brief warmth at the injection site, resolved within an hour. That’s it.
Honest Accounting
The boring truth is that this was a 2-pound change over 12 weeks, with a half-inch off the waist. I can’t prove AOD-9604 caused all of it. A 2-pound weight reduction over three months could be partially explained by natural variation, by small unintended fluctuations in caloric intake, or by a dozen other factors.
What I can say: the direction was consistent, the timeline tracked the published data, and nothing else in my protocol changed. My most honest assessment is that AOD-9604 produced a real but modest effect, and that the marketing claims around spot reduction or rapid fat loss are not supported by my experience or by the published trial data.
If you’re expecting a before-and-after transformation photo that would go viral on Instagram, this isn’t it. If you’re expecting a small, measurable nudge in a specific direction with essentially zero side effects, that’s closer to what I got.
Cost and What Comes Next
The 12-week protocol ran about $385 through FormBlends AOD-9604, the 503A compounding pharmacy fulfilling my prescription. The cost is modest by peptide standards. Whether the cost-effectiveness makes sense for a 0.6 percent body fat reduction is a legitimate question. I don’t have a definitive answer.
I’m currently off AOD-9604. The plan is to run a second 12-week block in four months, this time paired with a tighter caloric deficit, to see whether the combination produces more meaningful changes than either alone.
If the second block doesn’t produce more visible change, I’ll likely stop using AOD-9604 entirely and have a different conversation with my doctor about whether GLP-1 medication is worth considering for the specific localized issue.
If You’re Considering AOD-9604
Calibrate your expectations to the published Phase IIb data, not to the marketing. Modest fat loss over 12 weeks. No miracles.
Make sure your training and nutrition fundamentals are solid before adding a peptide for fat loss. AOD-9604 is not going to compensate for a bad diet or inconsistent training. It’s not even going to compensate for a mediocre diet.
Use a real prescriber and a 503A compounding pharmacy. The side effect profile appears clean, but regulatory and quality questions still matter. The grey-market peptide space is full of products with unknown purity and concentration, and saving $80 on a vial is not worth the uncertainty.
Track results carefully. The effect size is small enough that subjective evaluation is essentially useless. You need DEXA (or at minimum, a good caliper protocol), consistent photographs with identical lighting and posture, and tape measurements at fixed landmarks. Without those, you’ll either convince yourself it’s working when it isn’t or decide it’s not working when it is.
Twelve weeks in, modest results, clean tolerability. Worth continuing to test in my case, but I’d be lying if I said the effect was dramatic. It wasn’t. I think AOD-9604 occupies an odd niche: too subtle for people who want fast visible change, potentially useful for people who are already lean and looking for an incremental edge with a favorable safety profile.
Not FDA-approved. AOD-9604 is prescribed off-label and prepared by licensed 503A pharmacies for individual patients based on clinical judgment. Personal experience, not medical advice.
Frequently Asked Questions
How much fat loss can I realistically expect from AOD-9604 in 12 weeks? Based on the published Phase IIb data and my own test, expect modest overall fat loss in the range of 1 to 3 pounds over 12 weeks. The marketing often implies much more. Adjust expectations accordingly.
Does AOD-9604 work for spot reduction? The mechanism of selective lipolysis in specific fat depots has some preclinical support but is not strongly demonstrated in human trials. My experience showed modest overall fat reduction, not dramatic localized spot reduction.
Does AOD-9604 raise IGF-1 levels? In my 12-week test, IGF-1 remained at baseline throughout. This is consistent with the peptide’s design as a GH fragment that retains lipolytic activity without driving GH-axis effects.
What side effects does AOD-9604 have? In 12 weeks of daily 500 mcg subcutaneous injections, my only side effect was brief warmth at the injection site that resolved within an hour. No systemic effects. No lab changes.
How much does AOD-9604 cost? My 12-week protocol cost approximately $385 through a 503A compounding pharmacy. Costs vary depending on pharmacy, dosing, and prescriber fees.
Is AOD-9604 FDA-approved? No. AOD-9604 is not FDA-approved for any human indication in the United States. It is accessed through 503A compounding pharmacies under prescriber clinical judgment.
Should I use AOD-9604 instead of GLP-1 medications for fat loss? These are different tools with very different effect sizes. GLP-1 medications (semaglutide, tirzepatide) produce substantially greater weight loss but carry more side effects and cost. AOD-9604 is a much milder intervention. Discuss your specific situation with your prescriber.
